Safety of Sofosbuvir/Daclatasvir and Sofosbuvir/ Ribavirin in Children and Adolescents with Chronic Hepatitis C
Adil Hassan Chang, Ubedullah Bughio, Rehmatullah Bhatti, Laraib Jamali, Bushra Kadir & Muhammad Sadik Memon · Journal of Pharmaceutical Research International · 2022
Introduction: Sofosbuvir/ribavirin and sofosbuvir/ledipasvir regimes are approved by European Association for Study of Liver (EASL) for Chronic Hepatitis C (CHC) infection in adolescents although none of the combinations is approved for age below twelve years. Objective: The aim...
Open access
Research Article
10.9734/jpri/2022/v34i12B35557